Now showing items 1-5 of 5
A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment
The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evaluate hospital discharge planning in relation ...
Assessment of radioiodine clearance in patients with differentiated thyroid cancer
Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the management of differentiated thyroid cancer (DTC). Concerns regarding stochastic radiogenic risks have led to regulatory criteria ...
Chromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay
Objective: We evaluated the potential detrimental cytogenetic effects of 99mTc-methoxyisobutyl isonitrile (MIBI) and 131I on patients who were exposed to the radiopharmaceutics for cardiac imaging or thyroid cancer therapy, ...
Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma
Three days following administration of radioactive iodine in 38 patients, exposure rates such as dose rate close to the dress (D0), dose rate of dress at 1 m (D1), dose rate close to the bedsheet (B0), dose rate of bedsheet ...
Phase 2 study of a high dose of 186RE-HEDP for bone pain palliation in patients with widespread skeletal metastases
186Re-1-hydroxyethylidene-1,1-diphosphonate (HEDP) is an attractive radiopharmaceutical for the treatment of bone pain arising from skeletal metastatic lesions. Currently, 186Re-HEDP is most commonly used in European ...